Navigation Links
PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M
Date:7/30/2014

SCHOFIELD, Wis., July 30, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCPink:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is rebranding the LipiGesic® M name along with the name's red and yellow logo. The former will be replaced with the trademarked name MigraPure®  going forward. The new name, logo, and color palette of PuraMed's homeopathic, natural migraine pain reliever will be reintroduced into selected segments of the retail marketplace.

"We've been working on this for over a year," said Russell Mitchell, CEO and Chairman of PuraMed BioScience. "We needed to secure the trademark for the name and create the image before we announced the development of the enhanced formula and our product line extensions. 

"The new name will be easier for people to remember and pronounce," said Mitchell. "We also believe the new look and color of the logo will convey our 'safe' and 'natural' message at a glance. Preliminary feedback about the change has been positive and we are pleased. We will now have packaging that reflects the excellent product inside."

PuraMed hopes to have the new product, which uses a flavor-enhanced version of the sublingual LipiGesic M formula, new packaging, new price point, and a new website ready for public purchase within the next two months, though promotion and distribution to retailers and targeted wholesale partners will begin earlier.

"The manufacturing order has been placed," said Mitchell. "Our marketing plan is being finalized and as soon as the packaging and the website are ready, we will launch."

MigraPure's fresh look and message will replace the red and yellow LipiGesic logo. A tagline that describes the product will also be a fundamental part of the logo.

"By using a tagline with the image, we can make a stronger statement and leave no doubt in the consumer's mind about what MigraPure is or what it does, which is also an improvement," said Mitchell. "During the re-launch, we will also reference LipiGesic M on the packaging and other marketing materials in order to maintain a connection with our clinical trial data and our current customer base."

Development of the gel, packaging, and launch of the website are the first steps in the rebranding effort. PuraMed plans to continue to sell LipiGesic M under the old label until the new product is available.

A version of the new logo can be seen at www.lipigesic.com/MigraPure.

About MigraPure

MigraPure uses the same sublingual feverfew and ginger formula that was clinically tested as LipiGesic M. The flavor of this all-natural, over-the-counter migraine headache pain relief medication has been enhanced, but the active ingredients that stop disabling migraine pain and associated symptoms quickly, are the same. MigraPure's feverfew and ginger gel is non-drowsy and non-habit forming. MigraPure is not associated with rebound headaches. MigraPure has an excellent safety profile and has no reported drug interactions. 

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience plans to launch additional cannabinoid-enhanced, anti-inflammatory, and anxiolytic products as it moves forward in the development of its cannabinoid product line.

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages
2. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
3. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
4. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
5. Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
6. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
7. Ambit Biosciences To Announce Second Quarter 2014 Financial Results
8. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics Targeted Next Generation Sequencing Testing Platform
9. Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
10. Meditope Biosciences Appoints Prominent Scientific Advisory Board
11. Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  iCAD (Nasdaq: ICAD), an ... and radiation therapy for the early identification and ... Detection received Premarket Approval (PMA) from the U.S. ... is a first-of-its-kind, concurrent-read computer aided detection solution ... latest innovation available on the PowerLook® Breast Health ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal ... to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 ... revenue, and is projected to dominate the market during the study period. ... ... Logo ...
Breaking Medicine Technology:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for clear braces. People who want straight teeth without the extensive time ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... site attention and engagement over the household brands of Top-20 pharma by optimizing ... discuss how partnering with the right outsourcing payments provider can provide the technology, ...
(Date:3/27/2017)... ... ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, Vicki Mayo, was recently ... Mayo will present her pitch about the lifestyle wearable devices, Buzzies live ... ignites bold ideas by providing women access to the tools, training and networks needed ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the leading multimedia ... medicine, announces the launch of Veterinarian’s Money Digest™, a business and financial resource ... of American Veterinarian™. , “We look forward to launching Veterinarian’s Money ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... enables researchers to pursue the recent RNA methylation “gold rush” with their established ... of the newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has ...
Breaking Medicine News(10 mins):